Reimbursed Care Access in Sudan

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

There is no public record of a national regulatory approval, listing, or public reimbursement pathway for esketamine (Spravato) in Sudan; specialized intranasal esketamine products authorized in high‑income jurisdictions are not documented as approved or reimbursed in Sudanese regulatory sources. Ketamine (the racemate) is used clinically in Sudan as an essential injectable anaesthetic, but esketamine as a registered antidepressant formulation has not been identified in Sudanese public drug listings or health‑system procurement sources. [No national approval found in public sources; see national narcotics law context and WHO essential medicines listing for ketamine]. # #

Ketamine is a registered, widely used injectable anaesthetic in Sudan’s health system and is included on the WHO Model List of Essential Medicines as an injectable anaesthetic agent; Sudanese clinical literature and hospital surveys document routine ketamine availability and use for anaesthesia and emergency/surgical care in Sudan. Public reimbursement or a formal national mental‑health indication pathway for ketamine as a depression treatment (including infusion-based psychiatric protocols) is not documented—use is primarily as an anaesthetic in public and private hospitals, with procurement and availability varying by facility and region. Clinical/regulatory details: ketamine’s inclusion on the WHO essential medicines list supports its use in surgical and emergency contexts but does not create a national psychiatric reimbursement pathway in Sudan. Examples of Sudanese clinical publications reporting ketamine use in operating rooms and anesthesia practice are available. # # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (DMT is also listed under international psychotropic controls and Sudan implements national scheduling under its narcotics law.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Because ayahuasca preparations contain DMT (a scheduled psychotropic), ayahuasca is effectively treated as a controlled substance under Sudanese narcotics legislation with no authorised medical/religious exemption in public sources; therefore no legal medical access or reimbursement pathway exists outside approved clinical research. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (2C-series compounds are typically scheduled under national psychotropic substance controls; Sudan’s narcotics framework criminalises analogous synthetic psychedelics.) #